These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 08.09.2020 and posted on 09.09.2020by Vijayagopal Gopalsamuthiram, Corshai Williams, Jeffrey Noble, Timothy F. Jamison, B. Frank Gupton, David Snead
A new route to MK-4482 (1) was developed. The route
replaces uridine with the more available and less expensive cytidine. Low cost, simple reagents are used for the
chemical transformations and the yield is improved from 17% to 44%. A step is removed from the longest linear
sequence, and these advancements are expected to expand access to MK-4482
should it become a viable drug substance.